Delcath Systems (DCTH) Stock: If You Are Long, You Need To Call Your Broker!

0

Delcath Systems, Inc. (NASDAQ: DCTH) is having yet another incredibly rough day in the market today. As shorts continue to attack the stock, the price just continues to fall. In fact, the early morning drop today led to another alert from our friends at Trade Ideas. At the moment (9:57), DCTH is trading at $0.13 per share after a loss of $0.01 per share (6.21%) thus far today.





If You’re Long DCTH, It’s Time For You To Act

Delcath Systems is a company that I firmly believe in, and one that many others share the same views about. Unfortunately, the company and its loyal investors are falling victim to a horrible game that those without a conscious play quite often.




You see, While DCTH is working to bring a cure for specific types of cancer to the market, and their investors continue to put faith into the company, there are unethical investors out there trying to stop the progress. They are doing so through the process of shorting a stock. I’m not sure how they sleep at night when they are working to bring down a company that’s in the business of saving lives, but it seems to work for them.

The short attacks that are being waged, started by White Diamond Research through a short report of their own that was strewn with inaccurate and misleading information, are cutting into the bottom line for all who care about DCTH.

With that said, it’s time for you to act! In order for these unethical, greedy, money hungry bastards to get what they want, they need to borrow your shares. This is the only way to sell a stock short! To stop them, it’s important to make sure that your shares aren’t up for grabs. This means that it’s on you to call your broker and tell them that you don’t want your shares of Delcath Systems being loaned out to short sellers. If enough of those who truly believe in the company do so, you will essentially starve the market of shares available for loan, breaking the cycle of the short attack.

There’s A Bit Of An Elephant In The Room

At the moment, the short attacks on DCTH are leading to concerns among investors. These concerns are only being exacerbated by the fact that the company hasn’t released much news lately. Well, the truth of the matter is that they haven’t released any news lately. While I can see why this can be concerning to some, I urge you not to act on your emotions. The truth of the matter is that silence is a key part of this process.

Usually, when a company goes silent, it’s not because there’s something wrong. Instead, it’s because there is some big piece of news that they want to get out there, but have to wait for the right time to do so. In the mean time, we tend to see quiet periods. What the big news might be is really up to speculation. However, a quick look at the DCTH investor relations website will show you that the company likely has clinical data on the way relatively soon.

Why DCTH Is Worth Your Time

The bottom line here is that Delcath Systems isn’t a company fueled by horrible management and looking to take dollars out of investor pockets not to return them, as White Diamond Research (notice that the firm doesn’t offer the names of those spewing out this crap either) claims. Instead, as mentioned above, DCTH is a company that is in the business of saving lives.

While the shorts have torn the value of the stock down dramatically in recent times, we can’t forget the facts here. In April, DCTH celebrated more than 100 CHEMOSAT (it’s cancer treatment approved in Europe) treatments at Spire Southampton Hospital in the UK.

On top of that, the company is working diligently to bring this life-saving treatment to patients around the world. In the United States, there are multiple clinical studies taking place at the moment, and a New Drug Application is expected to be filed in 2019.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

The Bottom Line

The bottom line here is that DCTH is indeed a great company that is doing incredible things for patients fighting cancer. While they work to save lives, unethical investors are betting against the company and doing what they can to drag the price of the company’s shares to zero as quickly as possible. However, you can stop the bleeding. It’s time to call your broker and stop this mess before it gets too far out of hand!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









LEAVE A REPLY

Please enter your comment!
Please enter your name here